サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ブラキセラピーの世界市場-2023年～2030年
市場調査レポート
商品コード
1336762

ブラキセラピーの世界市場-2023年～2030年

Global Brachytherapy Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ブラキセラピーの世界市場-2023年～2030年
出版日: 2023年08月22日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界のブラキセラピー市場は2022年に8億米ドルに達し、2023年から2030年にかけてCAGR 8.1％で成長し、2030年には15億米ドルに達すると予測されています。

ブラキセラピー治療では、針やカテーテルを使って体内に埋め込むシード、ペレット、ワイヤー、カプセルに封入された放射性物質を使用します。この線源から放出される放射線は、近傍のがん細胞のDNAに損傷を与えます。ブラキセラピーは前立腺がんの治療に最もよく用いられます。

また、子宮頸がんや子宮体がん（子宮内膜がん）などの婦人科系がんや乳がんの治療にも用いられます。ブラキセラピーは、肺がん、直腸がん、眼がん、皮膚がんなど、その他のがんにも利用できます。さらに、がんの有病率の増加は、ブラキセラピー市場規模を上昇させる可能性があります。

米国やカナダのような国々での技術進歩の大規模な上昇により、市場は北米地域からの需要が増加しています。Perspective Therapeutics、Theragenics、Eckert & Ziegler、Civco Medical Solutionsなどの主要企業がこの市場で活発に活動しています。

ダイナミクス

前立腺がん罹患率の増加が市場成長を高める

前立腺がんの罹患率の増加は、市場の成長を高める可能性があります。例えば、米国がん協会によると、米国では2023年に約28万8,300人が新たに前立腺がんに罹患し、約3万4,700人が前立腺がんで死亡すると推定されています。

前立腺がんは、高齢男性と非ヒスパニック系黒人男性に発症しやすいです。10人に6人が65歳以上の男性で、40歳未満の男性ではまれです。初めて診断される男性の平均年齢は約66歳です。ブラキセラピー法は、前立腺がん細胞を死滅させるために放射性シード（ペレット）を前立腺に埋め込む方法です。

シードが放出する放射線の量は多い場合と少ない場合があります。多くの前立腺がん患者がブラキセラピーを必要としています。したがって、上記の要因は、前立腺がんの増加が市場の成長を高める可能性があることを示しています。

乳がん患者数の増加が市場成長を後押しする

例えば、CDCによると、米国では毎年、女性で約26万4,000例、男性で約2,400例の乳がんが診断されています。米国では毎年約42,000人の女性と500人の男性が乳がんで死亡しています。黒人女性は白人女性よりも乳がんによる死亡率が高いです。

間質性ブラキセラピーは乳がん患者に行われます。カテーテルと呼ばれる小さな中空の管を、切除しなければならないがんの部位の周囲の乳房に数本挿入し、数日間そのままにしておきます。放射性ペレットは毎日短時間カテーテルに挿入され、その後取り出されます。したがって、これらの前述の要因が市場成長の上昇を示しています。

治療に伴う副作用が市場成長を低下させる可能性

ブラキセラピーの副作用には、放射線が照射された場所の腫れ、あざ、出血、痛みや不快感などがあります。婦人科がんや前立腺がんに使用されるブラキセラピーは、失禁や排尿痛などの短期的な排尿症状を引き起こす可能性があります。

これらのがんに対するブラキセラピーは、下痢や便秘、直腸出血を引き起こすこともあります。前立腺のブラキセラピーは時に勃起不全を引き起こすことがあります。これらの上記の要因は、市場の成長を抑制する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 前立腺がんの罹患率の増加
      • 乳がん患者数の増加
    • 抑制要因
      • 治療に伴う副作用
    • 機会
      • 医療の進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 高線量ブラキセラピー
  • 低線量ブラキセラピー

第8章 適応症タイプ別

  • 前立腺がん
  • 婦人科がん
  • 乳がん
  • その他

第9章 エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Perspective Therapeutics
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な動向
  • Theragenics
  • Eckert & Ziegler
  • Civco Medical Solutions
  • Mirion Technologies
  • Elekta AB
  • IsoAid
  • Varian Medical Systems, Inc.
  • Prowess Inc.
  • RaySearch Laboratories

第13章 付録

目次
Product Code: PH1233

Overview

The Global Brachytherapy Market reachedUS$ 0.8 Billion in 2022 and is expected to reach US$ 1.5 Billion by 2030, growing with a CAGR of 8.1%during the forecast period 2023-2030.

Brachytherapy treatment uses radioactive material sealed inside a seed, pellet, wire, or capsule implanted in the body using a needle or catheter. The radiation given off by this source damages the DNA of nearby cancer cells. Brachytherapy is most commonly used to treat prostate cancer.

It also can be used for gynecologic cancers such as cervical cancer and uterine (endometrial) cancer, as well as breast cancer. Brachytherapy can also be utilized in others cancers including lung cancer, rectal cancer, eye cancer, and skin cancer. Furthermore, the increase in the prevalence of cancer can elevate the brachytherapy market size.

Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market experience increased demand from North American regions. Significantkey players like Perspective Therapeutics, Theragenics, Eckert & Ziegler, Civco Medical Solutions, and others are actively operating in the market.

Dynamics

The Growing Incidence of Prostate Cancer can Elevate the Market Growth

The increase in the incidence of prostate cancer can elevate the growth of the market. For instance, according to the American Cancer Society about 288,300 new cases of prostate cancer are estimated in the United States in 2023 and around 34,700 deaths are estimated from prostate cancer.

Prostate cancer is more likely to develop in older men and in non-hispanic black men. About 6 cases in 10 are diagnosed in men 65 or older, and it is rare in men under 40. The average age of men when they are first diagnosed is about 66 years. Brachytherapy procedure is used to implant radioactive seeds (pellets) into the prostate gland to kill prostate cancer cells.

The seeds may give off high or low amounts of radiation. Numerous patients with prostate cancer require brachytherapy. Thus, above mentioned factors demonstrate that an increase in prostate cancer can elevate market growth.

Rise in the Number of Breast Cancer Cases can Boost the Market Growth

An increase in the number of breast cancer cases can accelerate the growth of the market.For instance, according to CDC, each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 in men. About 42,000 women and 500 men in the U.S. die each year from breast cancer. Black women have a higher rate of death from breast cancer than white women.

Interstitial brachytherapy is performed on breast cancer patients. Several small, hollow tubes called catheters are inserted into the breast around the area at the site of the cancer that has to be removed and are left in place for several days. Radioactive pellets are inserted into the catheters for short periods of time each day and then removed. Thus, these aforementioned factors shows the rise in the market growth.

Side Effects Associated with the Treatment can Decline the Market Growth

Side effects of brachytherapy can include swelling, bruising, bleeding, or pain and discomfort at the spot where the radiation was delivered. Brachytherapy used for gynecologic or prostate cancer can lead to short-term urinary symptoms, including incontinence or pain in urination.

Brachytherapy for these cancers can also lead to diarrhea, constipation, and rectal bleeding. Prostate brachytherapy can occasionally cause erectile dysfunction. These above mentioned factors may restrain the market growth.

Segment Analysis

The global brachytherapy market is segmented based on type, indication type, end-user and region.

High Dose Rate Brachytherapy SegmentAccounted for Approximately 39.6% of the Brachytherapy Market Share

High dose rate brachytherapy segment is expected to hold a significant position in the brachytherapy market share. In high dose-rate brachytherapy, the tumour is exposed to a high dosage of radiation but the surrounding organs are greatly spared. Radiation that is administered at a high dose-rate or at a high dose per fraction is known to be particularly sensitive to prostate cancer.

Lower toxicity than with low dosage-rate implants is achieved through quick administration and good dose conformity. Several researches have suggested that the high or intermediate risk patients who are suitable should be provided with high dose rate brachytherapy (HDR) in combination with external beam radiotherapy since it has a greater rate of cancer control than external beam alone.

A single 15 Gy HDR in conjunction with 40-50 Gy external beam radiation yields a disease-free survival rate of over 90% for moderate risk and 80% for high risk, despite the fact that different doses and fractionations have been employed. Thus, the rising research studies by the researchers are expected to raise the growth of the segment.

Geographical Penetration

North America Accounted for Approximately 42.1% of the Market Share in 2022.

North America is expected to hold a significant position in the brachytherapy market share. The increase in technological advancements in healthcare and the agreements by the companies can elevate the growth of the market in this region. For instance, on July 23, 2021, Elekta (EKTA-B.ST) announced that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron brachytherapy afterloader systems, including service agreements.

The cancer treatment devices will allow GenesisCare to continue to invest in the latest world-class technology while providing access to high-quality care to their patients throughout their U.S. centers. GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide, and Elekta is delighted to play a vital partnering role in achieving this mission. Thus, an increase in the strategic initiatives by the key players can elevate the growth of the market.

Competitive Landscape

The major global players in the brachytherapy market include Perspective Therapeutics, Theragenics, Eckert & Ziegler, Civco Medical Solutions, Mirion Technologies, Elekta AB, IsoAid, Varian Medical Systems, Inc., Prowess Inc., RaySearch Laboratories among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant influence on the brachytherapy market, posing unprecedented challenges to many countries. The delay in the diagnosis of cancers and also the delay in the treatment procedures have created a negative impact on the growth of the market. The reduction in the advancements and investments by the key companies has created a significant decline in the growth of the market. Thus, COVID-19 has created a negative impact on the growth of the market.

By Type

  • High-Dose Brachytherapy
  • Low-Dose Brachytherapy

By Indication Type

  • Prostate Cancer
  • Gynecological Cancer
  • Breast Cancer
  • Others

By End-User

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On July 14, 2023, BEBIG Medical, a global provider of high-quality radiation therapy products, is pleased to announce its successful bid in the Ministry of Health (MOH) tender in Indonesia. BEBIG Medical has been awarded contracts to supply 6 units of HDR (high dose rate) brachytherapy equipment to hospitals across the country. This achievement highlights BEBIG Medical's commitment to delivering cutting-edge medical technology to support cancer treatment in Indonesia.
  • On April 20, 2023, Elekta announced that an estimated two million brachytherapy treatments have been delivered by healthcare providers using Flexitron high dose rate (HDR) afterloader. One site that has contributed to this treatment milestone is Amsterdam University Medical Centers (Amsterdam UMC) in the Netherlands, which acquired the 1,000th Flexitron recently manufactured at Elekta's facility in Veenendaal.
  • On January 5, 2023, C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. has received U.S. Food and Drug Administration (FDA) clearance for the use of C4 Imaging's Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray's Cesium-131, brachytherapy seeds.

Why Purchase the Report?

  • To visualize the global brachytherapy market segmentation based on type, indication type, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of brachytherapy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available in Excel consisting of key products of all the major players.

The global brachytherapy market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Indication Type
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Incidence of Prostate Cancer
      • 4.1.1.2. Rise in the Number of Breast Cancer Cases
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with the Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Advancements in Healthcare
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. High-Dose Brachytherapy
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Low-Dose Brachytherapy

8. By Indication Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
    • 8.1.2. Market Attractiveness Index, By Indication Type
  • 8.2. Prostate Cancer
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Gynecological Cancer
  • 8.4. Breast Cancer
  • 8.5. Others

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgery Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Perspective Therapeutics
    • 12.1.1. Company Overview
    • 12.1.2. ProductPortfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Theragenics
  • 12.3. Eckert & Ziegler
  • 12.4. Civco Medical Solutions
  • 12.5. Mirion Technologies
  • 12.6. Elekta AB
  • 12.7. IsoAid
  • 12.8. Varian Medical Systems, Inc.
  • 12.9. Prowess Inc.
  • 12.10. RaySearch Laboratories

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us